ALGENEX and the Spanish National Institute of Agricultural and Food Research (INIA) sign several agreements for the company incubation, products development and for the exploitation in exclusive of several ALGENEX-INIA joint patents.

ALGENEX received funds from Comunidad de Madrid autonomous government and the Spanish Ministry of Industry for developing products and technologies.

ALGENEX, VIVACELL Spain and BYBIOTECH create a consortium to produce recombinant growth factors and biomimetic polypeptides with application as dermocosmetic products and as therapeutic molecules.

ALGENEX licenses to the Swedish company SVANOVA diagnostic reagents to develop African swine fever kits.

ALGENEX and the Argentinean company INMUNOVA sign an agreement of joint-development of a recombinant subunit vaccine against pandemic and seasonal influenza based on the adjuvant molecule BLS. This molecule stimulates innate immunity through the Toll-like receptor 4, presenting unique immune potentiating advantages.

ALGENEX and the CReSA foundation from the Universidad Autónoma de Barcelona, Spain, sign an agreement to develop a recombinant subunit vaccine against porcine circovirus based on virus proteins produced by the IBES technology.

ALGENEX and the Institute of Virology CICVyA INTA Castelar from Buenos Aires, Argentina, sign an agreement for joint-development of a subunit vaccine against the Bovine virus diarrhea virus based on the adjuvant molecule APCH1 property of ALGENEX .

ALGENEX and the Unitat de Farmacologia Veterinària, Dept. Farmacologia, Terapèutica i Toxicologia, from the Universidad Autónoma de Barcelona, Spain, sign an agreement to develop diagnostic and vaccine formulations against Leishmania parasite based on recombinant proteins produced by the IBES technology.

ALGENEX and the Institute of Virology CICVyA INTA Castelar from Buenos Aires, Argentina, sign an agreement for joint-development of the Rotavir-block therapeutic molecule with exclusive world wide license of exploitation in favor of ALGENEX .

ALGENEX and the Spanish company BIOKIT sign an agreement for development of human diagnostic reagents for infectious diseases produced by the IBES technology.

.